Annals of Hematology

, Volume 89, Issue 10, pp 1069–1070

Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series

  • Rita Coutinho
  • Dolors Costa
  • Ana Carrió
  • Concha Muñoz
  • Ana Vidal
  • Mohammed Belkaid
  • Elias Campo
  • Benet Nomdedeu
Letter to the Editor
  • 108 Downloads

References

  1. 1.
    Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, Kundgen A, Lubbert M, Kunzmann R, Giagounidis AA, Aul C, Trumper L, Krieger O, Stauder R, Muller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385–4395CrossRefPubMedGoogle Scholar
  2. 2.
    Haase D (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87:515–526CrossRefPubMedGoogle Scholar
  3. 3.
    Steensma DP, List A (2005) Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 80(5):681–698CrossRefPubMedGoogle Scholar
  4. 4.
    List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456–1465CrossRefPubMedGoogle Scholar
  5. 5.
    Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A (2008) Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet 187:101–111CrossRefPubMedGoogle Scholar
  6. 6.
    Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Lilienfeld-Toal MV, Wells RA (2008) Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Ann Hematol 87:345–352CrossRefPubMedGoogle Scholar
  7. 7.
    Giagounidis AA, Haase S, Heinsch M, Gohring G, Schlegelberger B, Aul C (2007) Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q) MDS patients with unexpected responses. Ann Hematol 86:133–137CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Rita Coutinho
    • 1
  • Dolors Costa
    • 2
  • Ana Carrió
    • 2
  • Concha Muñoz
    • 2
  • Ana Vidal
    • 2
  • Mohammed Belkaid
    • 1
  • Elias Campo
    • 2
  • Benet Nomdedeu
    • 1
  1. 1.Institute of Hematology and Oncology, Department of Hematology, Hospital Clinic IDIBAPSUniversity of BarcelonaBarcelonaSpain
  2. 2.Hematopathology Unit, Hospital Clinic IDIBAPSUniversity of BarcelonaBarcelonaSpain

Personalised recommendations